Andrew P. Han
Andrew Han covers breaking news for GenomeWeb. He tracks companies in the sequencing and diagnostic markets.

Articles Authored by Andrew P. Han
In addition to proving clinical utility, the startup will have to navigate issues of regulatory strategy, sequencing technology, and additional indications.
European Commission Fines Illumina €432M For Prematurely Closing Grail Acquisition
The EC also fined Grail €1,000, a symbolic amount and the first instance of imposing a fine on a company that was the target of a prematurely closed acquisition.
Illumina Appeals FTC's Order to Divest Grail, Cites Government Overreach
In its petitioner's brief, Illumina and Grail called the FTC an "unconstitutional agency" and ask the court to revers the commission's decision.
Using Arima's technology, NYU researchers were able to identify a novel rearrangement in the PDL-1 gene in a pediatric brain tumor, which led to treatment with immunotherapy.
POC Genotyping Tests Based on Electromagnetic Detection Tech Step out From Stanford University Lab
Premium
Spinout Magic LifeScience is leading commercialization of the molecular diagnostic technology, but the tests are popping up in other clinical scenarios, too.
US Federal Trade Commission Orders Illumina to Unwind Grail Acquisition
Illumina plans to appeal the decision, seeking a resolution by late 2023 or early 2024, but now faces a third source of pressure to divest Grail.
SomaLogic CEO Steps Down Amid Board Turnover; Firm's Q4 Revenues Drop 18 Percent
Ex-CEO Roy Smythe is one of three people stepping down from the board. He will be replaced by Adam Taich, formerly executive VP of life sciences at SomaLogic.
Thermo Fisher Scientific's IonTorrent Genexus platform can provide cancer panel results in about a day, but data on clinical impact of the fast turnaround has not yet been produced.
Layoffs at Life Science, Dx Firms Continue as Thermo Fisher Scientific, Natera Shrink Payrolls
In 2023, Thermo Fisher has laid off nearly 400 California employees at sites associated with Mesa Biotech, acquired in 2021 for $450 million in cash.
SomaLogic Seeks 'Strategic Alternatives' for Dx Business to Focus on Life Science Market
The proteomics firm is in talks to either spin off its SomaSignal assays unit or to partner with another company to boost its diagnostics efforts.